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AbsTrACT
Objectives To compare efficacy and safety of 
ixekizumab (iXe) to adalimumab (aDa) in biological 
disease-modifying antirheumatic drug-naïve patients 
with both active psoriatic arthritis (Psa) and skin disease 
and inadequate response to conventional synthetic 
disease-modifying antirheumatic drug (csDMaRDs).
Methods Patients with active Psa were randomised 
(1:1) to approved dosing of iXe or aDa in an open-label, 
head-to-head, blinded assessor clinical trial. The primary 
objective was to evaluate whether iXe was superior 
to aDa at week 24 for simultaneous achievement of 
a ≥50% improvement from baseline in the american 
College of Rheumatology criteria (aCR50) and a 100% 
improvement from baseline in the Psoriasis area and 
severity index (Pasi100). Major secondary objectives, 
also at week 24, were to evaluate whether iXe was: 
(1) non-inferior to aDa for achievement of aCR50 and 
(2) superior to aDa for Pasi100 response. additional 
Psa, skin, treat-to-target and quality-of-life outcome 
measures were assessed at week 24.
results The primary efficacy endpoint was met (iXe: 
36%, aDa: 28%; p=0.036). iXe was non-inferior for 
aCR50 response (iXe: 51%, aDa: 47%; treatment 
difference: 3.9%) and superior for Pasi100 response 
(iXe: 60%, aDa: 47%; p=0.001). iXe had greater 
response versus aDa in additional Psa, skin, nail, treat-
to-target and quality-of-life outcomes. serious adverse 
events were reported in 8.5% (aDa) and 3.5% (iXe) of 
patients.
Conclusions iXe was superior to aDa in achievement 
of simultaneous improvement of joint and skin 
disease (aCR50 and Pasi100) in patients with Psa 
and inadequate response to csDMaRDs. safety and 
tolerability for both biologicals were aligned with 
established safety profiles.
InTrOduCTIOn
The goal of treatment in patients with active psori-
atic arthritis (PsA) is to simultaneously improve the 
manifestations of the disease, including arthritis 
and skin disease. Improvements in both joint 
and skin disease are necessary to achieve optimal 
improvement in health-related quality of life in 
Key messages
What is already known about this subject?
 ► Many patients with psoriatic arthritis and 
active skin and joint disease do not achieve 
satisfactory clinical response with conventional 
synthetic disease-modifying antirheumatic 
therapy in both important domains of the 
disease simultaneously.
 ► In this patient group, biological disease-
modifying antirheumatic drugs (bDMARDs) 
offer additional treatment options, but the 
comparative efficacy and safety of bDMARDs is 
not known.
What does this study add?
 ► The findings of this study demonstrate that 
ixekizumab was superior to adalimumab for 
simultaneous achievement of American College 
of Rheumatology 50 (ACR50) and Psoriasis Area 
and Severity Index (PASI100), was non-inferior 
to adalimumab for achievement of ACR50 and 
was superior to adalimumab for achievement of 
PASI100 at week 24.
 ► Response with ixekizumab was significantly 
greater than adalimumab for Minimal Disease 
Activity, Very Low Disease Activity, Disease 
Activity in Psoriatic Arthritis remission (≤4), 
change from baseline in modified Composite 
Psoriatic Disease Activity Index, resolution 
of enthesitis (Spondyloarthritis Research 
Consortium of Canada Enthesitis Index=0), 
PASI75, PASI90 and Dermatology Life Quality 
Index (0 or 1) and was at least similar to 
adalimumab for all other psoriatic arthritis, 
treat-to-target, skin, nail and quality of life 
endpoints.
How might this impact on clinical practice or 
future developments?
 ► The findings of this study increase awareness 
of current treatment options and informs 
evidence-based treatment decisions for patients 
with active psoriatic arthritis and active 
psoriatic skin disease.
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patients with PsA, an important indicator of treatment success.1 
Treatment options for patients with PsA include non-pharma-
cological intervention, symptomatic treatment, conventional 
synthetic disease-modifying antirheumatic drugs (csDMARDS), 
biological DMARDs (bDMARDs) and other immunomodula-
tory therapies.2–6
Among patients who fail to achieve adequate response to 
csDMARDs, bDMARDs targeting inflammatory cytokines such 
as tumour necrosis factor α (TNF), interleukin (IL)-12/23 or 
IL-17A offer an alternative either as a combination therapy with 
csDMARDs or as monotherapy. Some evidence suggests that 
combination therapy with csDMARDs such as methotrexate may 
inhibit development of antidrug antibodies to bDMARDs, and 
some studies observed better treatment persistence with combi-
nation therapy.7 Concomitant methotrexate has been associated 
with greater serum concentration of adalimumab (ADA) versus 
patients receiving ADA monotherapy.8
The objective of the current study is to determine whether 
ixekizumab (IXE), a high-affinity monoclonal antibody that 
selectively targets IL-17A, is superior to ADA, a TNF inhib-
itor, as measured by a combined arthritis and skin endpoint 
in bDMARD-naïve patients with active PsA and inadequate 
response to csDMARDs. Concomitant use of a stable dose of 
csDMARDs was permitted during the study.
MeTHOds
Participants
Eligible participants had an established diagnosis of PsA for at 
least 6 months, fulfilled the Classification for Psoriatic Arthritis 
criteria with at least 3/66 swollen and 3/68 tender joints, had 
previous inadequate response to ≥1 csDMARD, had active 
plaque psoriasis affecting ≥3% of body surface area (BSA) and 
had not previously received bDMARD or Janus kinase inhibitor 
therapy.9 Patients on csDMARDs at screening were allowed to 
continue a stable dose of csDMARD therapy.
study design
This study is a 52 week, phase IIIb/IV, multicentre, randomised, 
open-label, blinded-assessor, parallel-group study evaluating 
the efficacy and safety of IXE versus ADA in bDMARD-naïve, 
csDMARD-inadequate-responder patients (based on medical 
history) with active PsA. Following a 28-day screening period, 
participants were randomised 1:1 to open-label IXE or ADA 
during a 52-week open-label treatment period (weeks 0–52). 
Randomisation was stratified by concomitant csDMARD use at 
baseline and moderate-to-severe plaque psoriasis involvement 
(Psoriasis Area and Severity Index (PASI)≥12, BSA ≥10% and 
static physician’s global assessment (sPGA) ≥3). Study visits 
occurred at screening, baseline and postbaseline at weeks 1, 4, 
8, 12, 16, 24, 32, 40 and 52. Treatment allocation was revealed 
after randomisation to sponsors, investigators, patients and all 
study staff except for blinded assessors. Blinded assessors eval-
uated tender joint count, swollen joint count, PASI, % BSA, 
enthesitis, Leeds Dactylitis Index–Basic (LDI-B), Nail Psoriasis 
Severity Index (NAPSI) fingernails and sPGA.
Participants received approved-label dosing of assigned treat-
ments by subcutaneous injection. All patients randomised to 
IXE received a 160 mg starting dose (two 80 mg injections) at 
week 0. IXE-treated patients received 80 mg IXE every 4 weeks 
from week 4 onwards (seven doses up to week 24) unless they 
met criteria for moderate-to-severe psoriasis, in which case they 
received 80 mg IXE every 2 weeks from week 2 to week 12, 
followed by IXE every 4 weeks (10 doses up to week 24, three 
additional doses). Patients randomised to ADA received a 40 mg 
starting dose followed by 40 mg ADA every 2 weeks starting 
at week 2 (12 doses up to week 24), or if they met criteria for 
moderate-to-severe psoriasis, they received an 80 mg starting 
dose of ADA (two 40 mg injections) at week 0, followed by 40 
mg ADA every 2 weeks starting at week 1 (14 doses up to week 
24, two additional doses). Thus, among patients with moder-
ate-to-severe psoriasis, the IXE dosing regimen resulted in one 
more additional dose relative to those receiving ADA.
SPIRIT-H2H ( Clinicaltrials. gov: NCT03151551) was 
conducted in accordance with the ethical principles of the 
Declaration of Helsinki. All patients provided written informed 
consent, and the study protocol was approved by the ethical 
review board prior to the start of study-related procedures.
Patient and public involvement
Patients were not involved in the design or conduct of the study, 
development of outcomes or dissemination of study results.
efficacy endpoints
The primary and two major secondary endpoints were tested 
using a sequential hierarchical testing procedure in the order 
presented below. There were no adjustments for multiple 
comparisons for any other analyses.
Primary endpoint (simultaneous achievement of ACR50 and 
PASI100)
The primary endpoint assessed superiority of IXE versus ADA at 
week 24, as measured by the proportion of patients who simul-
taneously achieved an American College of Rheumatology 50 
(ACR50) response and PASI100 response. After the week 24 
database lock and initial analysis run, a medical inconsistency 
in baseline PASI data was identified (PASI=0 but BSA ≥3%) in 
nine patients. This scenario was not anticipated or described in 
the protocol or statistical analysis plan. The inconsistency was 
resolved using medical judgement. The impacted patients met 
baseline criteria for active psoriasis. In the final primary anal-
ysis, patients with baseline PASI=0 and BSA ≥3 were consid-
ered PASI100 responders if, and only if, an absolute PASI=0 and 
BSA=0 was achieved at week 24. Multiple analyses to assess the 
robustness of this approach were conducted (see online supple-
mentary table 1).
Major secondary endpoint 1 (ACR50)
Major secondary endpoint 1 assessed whether IXE was non-in-
ferior to ADA at week 24 as measured by the proportion of 
patients achieving ACR50.
Major secondary endpoint 2 (PASI100)
Major secondary endpoint 2 assessed whether IXE was superior 
to ADA at week 24 as measured by the proportion of patients 
achieving PASI100.
Other secondary endpoints
Additional prespecified outcomes included the proportion of 
patients achieving ≥20% or ≥70% improvement from base-
line in ACR criteria (ACR20/70), ≥75% or ≥90% improve-
ment from baseline in PASI (PASI75/90), resolution of fingernail 
psoriasis (NAPSI fingernails=0), PsA minimal disease activity 
(MDA), a minimal clinically important difference (MCID) of 
≥0.35-point improvement from baseline in Health Assessment 
Questionnaire–Disability Index (HAQ-DI) among patients with 
≥0.35 at baseline, a Dermatology Life Quality Index score of 
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Figure 1 Participant flow diagram up to week 24.
0 or 1 (DLQI (0 or 1)), resolution of enthesitis as measured by 
the Spondyloarthritis Research Consortium of Canada Enthesitis 
Index (SPARCC Enthesitis Index=0) or Leeds Enthesitis Index 
(LEI=0) among patients with enthesitis at baseline (SPARCC 
Enthesitis Index >0 or LEI >0) and resolution of dactylitis as 
measured by the Leeds Dactylitis Index–Basic (LDI-B=0) among 
patients with dactylitis at baseline (LDI-B >0). Prespecified 
continuous outcomes included the mean change from baseline 
in NAPSI and the modified Composite Psoriatic Disease Activity 
Index (mCPDAI) (see online supplementary table 2).
Post hoc continuous analyses included mean change from base-
line in Disease Activity in Psoriatic Arthritis (DAPSA) and in the 
psoriatic arthritis disease activity score (PASDAS). Post hoc cate-
gorical analyses included the percentage of patients achieving 
DAPSA ≤4 (remission), DAPSA ≤14 (low disease activity or 
remission), PASDAS ≤3.2 (low disease activity), PASDAS ≤1.9 
(near remission) and meeting 7/7 MDA criteria (very low disease 
activity (VLDA)).
safety
Treatment-emergent adverse events (TEAEs) were defined as 
events that first occurred or worsened in severity after the first 
dose of study treatment and on or prior to the date of the last 
visit within the treatment period. AEs of special interest included 
infections, injection-site reactions, cytopaenias, liver function 
test changes/enzyme elevations, allergic reactions/hypersensi-
tivity, cerebrocardiovascular events, malignancies, depression 
and suicide/self-injury, interstitial lung disease and inflamma-
tory bowel disease (IBD). Data relating to cerebrocardiovascular 
events and suspected IBD were adjudicated by external clinical 
events committees.
statistical analyses
Analyses of efficacy were performed at the week 24 primary 
database lock for the intent-to-treat population, consisting of all 
randomised patients according to treatment assigned at week 0. 
A hierarchical multiple testing procedure for the primary and 
two major secondary endpoints was implemented to control 
the family-wise type I error rate at a two-sided α level of 0.05. 
The first test in the statistical hierarchy was a superiority test 
of the primary endpoint (simultaneous ACR50 and PASI100). 
If IXE was determined to be statistically superior to ADA for 
the primary endpoint, a non-inferiority test of IXE versus ADA 
was performed for secondary endpoint 1 (ACR50). If the test 
for major secondary endpoint 1 was successful (indicating IXE 
was non-inferior to ADA for achieving ACR50 at Week 24), a 
superiority test was conducted for major secondary endpoint 2 
(PASI100). If a test in this sequence was not successful, all subse-
quent tests were considered unsuccessful.
A fixed-margin approach was used for non-inferiority testing 
of ACR50 response, where IXE was deemed non-inferior to ADA 
if the lower bound of the two-sided 95% CI for the difference 
in proportions of ACR50 responders on IXE minus ADA was 
greater than the prespecified margin of −12.0%. This non-infe-
riority margin represents an approximately 50% preservation of 
the ADA treatment effect observed in historical phase III studies 
per Food and Drug Administration (FDA)/European Medicines 
Agency (EMA) non-inferiority study design guidelines.10–13
Categorical efficacy and health outcome variables were anal-
ysed based on treatment success/failure using a logistic regression 
model with treatment, concomitant csDMARD use at baseline 
and moderate-to-severe plaque psoriasis involvement as factors. 
Patients were considered treatment failures (or non-responders) 
if they did not meet the clinical response criteria or had missing 
clinical response data at a particular time point of analysis.
Continuous variables were analysed using a mixed effects 
model of repeated measures analysis, which included treatment 
group, concomitant csDMARD use at baseline, moderate-to-se-
vere plaque psoriasis involvement and visit as fixed factors; 
baseline value as covariate; and baseline-by-visit and treatment-
by-visit interaction terms. Missing data were imputed using a 
modified baseline observation carried forward method.
Descriptive safety analyses were performed on all randomised 
patients according to assigned treatment who received ≥1 dose 
of study treatment and included all data available up to the time 
of database lock.
resulTs
Participants
Of 684 patients screened, 566 were randomised between 24 
August 2017 and 24 May 2018, to either ADA (n=283) or 
IXE (n=283); 269 (95%) patients randomised to ADA and 262 
(93%) patients randomised to IXE completed the week 24 study 
visit (figure 1). Baseline demographics and disease characteristics 
were balanced between treatment groups (table 1). All patients 
had active plaque psoriasis with BSA ≥3%.
efficacy
Efficacy outcomes at week 24 are summarised in table 2. The 
primary and all major secondary endpoints of the study were 
met. The proportion of patients simultaneously achieving ACR50 
and PASI100 was significantly (p=0.036) greater for patients 
receiving IXE (36%) than ADA (28%); significant differences 
were observed as early as week 8 (figure 2A). IXE was non-in-
ferior to ADA as measured by ACR50 response (IXE: 50.5%, 
ADA: 46.6%, IXE vs ADA treatment difference: 3.9% (95% CI 
−4.3% to 12.1%)); there were no statistically significant differ-
ences in ACR50 response between treatment arms (figure 2B). 
PASI100 response was significantly (p=0.001) greater in the IXE 
(60%) versus ADA (47%) group; statistically significant differ-
ences were observed as early as the first PASI assessment (week 
4) and persisted through week 24 (figure 2c).
Significantly more patients achieved PsA MDA (treatment 
difference: 12.4%, 95% CI 4.3% to 20.4%) and VLDA (treat-
ment difference: 7.1%, 95% CI 1.4% to 12.7%) at week 24 in 
the IXE versus ADA groups (figure 3A,B). Although there were 
no significant differences between treatment groups in DAPSA 
change from baseline (treatment difference: −1.64, 95% CI 
−3.94 to 0.66) or DAPSA low disease activity, including remis-
sion (DAPSA ≤14) (treatment difference: 1.1%, 95% CI −7.0% 
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Table 1 Baseline demographics and disease characteristics
IXe (n=283) AdA (n=283)
Baseline demographics
Age, years 47.5 (12.0) 48.3 (12.3)
Sex, n (%)
  Male 162 (57) 150 (53)
  Female 121 (43) 133 (47)
Race, n (%)
  White 222 (78) 211 (75)
  Asian 29 (10) 33 (12)
Weight, kg 85.3 (19.8) 81.9 (18.3)
Body mass index, kg/m2 30.0 (6.9) 29.7 (8.3)
Duration of symptoms since PsA diagnosis, 
years
6.6 (7.4) 5.9 (6.4)
Duration of symptoms since psoriasis 
diagnosis, years
16.1 (13.1) 14.7 (12.6)
Concomitant csDMARD use, n (%) 193 (68) 199 (70)
Concomitant methotrexate use, n (%) 167 (59) 169 (60)
Baseline disease scores
Tender joint count 19.1 (12.7) 21.3 (15.4)
Swollen joint count 10.1 (7.5) 10.7 (8.1)
Patient pain VAS 59.7 (21.9) 62.4 (21.1)
Patient’s global assessment of disease 
activity VAS, mm
62.4 (20.3) 65.2 (20.7)
Physician’s global assessment of disease 
activity VAS, mm
58.9 (17.5) 59.4 (18.2)
HAQ-DI 1.2 (0.6) 1.3 (0.7)
C-reactive protein, mg/L 9.8 (13.7) 10.5 (19.3)
SPARCC Enthesitis Index >0, n (%) 189 (67) 171 (60)
SPARCC Enthesitis Index* 4.9 (3.5) 5.7 (3.8)
LEI >0, n (%) 159 (56) 147 (52)
LEI† 2.5 (1.4) 2.7 (1.5)
LDI-B >0, n (%) 42 (15) 58 (21)
LDI-B‡ 40.1 (42.4) 55.8 (128.4)
PASDAS 5.8 (0.9) 5.8 (1.0)
DAPSA 42.7 (20.6) 45.8 (23.5)
Moderate-to-severe psoriasis, n (%) 49 (17) 51 (18)
PASI ≥12, n (%) 55 (19) 57 (20)
sPGA ≥3, n (%) 173 (61) 181 (64)
BSA ≥3%, n (%) 283 (100) 283 (100)
BSA ≥10%, n (%) 113 (40) 104 (37)
PASI 7.9 (8.7) 7.7 (7.3)
Percentage BSA 14.8 (18.4) 12.9 (15.6)
DLQI 9.8 (7.6) 9.8 (7.6)
NAPSI fingernails >0, n (%) 191 (68) 177 (63)
NAPSI fingernails§ 19.7 (18.5) 19.1 (16.3)
Unless indicated otherwise, data are presented as mean (SD).
*Assessed in patients with SPARCC Enthesitis Index >0 at baseline.
†Assessed in patients with LEI >0 at baseline.
‡Assessed in patients with LDI-B >0 at baseline.
§Assessed in patients with NAPSI >0 at baseline.
ADA, adalimumab; BSA, body surface area; csDMARD, conventional synthetic 
disease-modifying antirheumatic drug; DAPSA, Disease Activity in Psoriatic Arthritis; 
DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire–
Disability Index; IXE, ixekizumab; LDI-B, Leeds Dactylitis Index–Basic; LEI, Leeds 
Enthesitis Index; NAPSI, Nail Psoriasis Area and Severity Index; PASDAS, psoriatic 
arthritis disease activity score; PASI, Psoriasis Area and Severity Index; PsA, psoriatic 
arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; sPGA, static 
physician’s global assessment; VAS, visual analogue scale.
to 9.1%) at week 24 (figure 3C), significantly more patients 
achieved the more stringent DAPSA remission (DAPSA ≤4) in 
the IXE versus ADA group (treatment difference: 8.5%, 95% CI 
1.7% to 15.3%) (figure 3D). There were no significant differ-
ences between treatment groups in PASDAS change from baseline 
(treatment difference: −0.14, 95% CI −0.38 to 0.10) or PASDAS 
low disease activity (PASDAS ≤3.2) (treatment difference: 6.0%, 
95% CI −2.2% to 14.2%), but PASDAS near remission (PASDAS 
≤1.9) was achieved by significantly more patients in the IXE 
than ADA group (treatment difference: 9.5%, 95% CI 2.5% 
to 16.6%). No significant differences were observed in ACR20 
(treatment difference: −3.2%, 95% CI −10.7% to 4.3%) or 
ACR70 (treatment difference: 6.0%, 95% CI −1.4% to 13.5%). 
Change from baseline in mCPDAI was significantly greater in the 
IXE versus ADA group at week 24 (treatment difference: −0.53, 
95% CI −0.85 to −0.20), with statistically significant improve-
ments as early as the first assessment at week 12.
SPARCC Enthesitis Index=0 was achieved by significantly 
more patients in the IXE versus ADA group at week 24 (treat-
ment difference: 11.6%, 95% CI 1.3% to 21.9%). Both IXE and 
ADA were efficacious as measured by LDI-B=0 response, but 
there were no statistically significant differences between treat-
ment groups in LDI-B=0 response up to week 24 (treatment 
difference: −5.0%, 95% CI −16.8% to 6.8%).
Significantly more patients achieved PASI75 (treatment 
difference: 11.3%, 95% CI 4.2% to 18.4%) and PASI90 
(treatment difference: 15.9%, 95% CI 8.1% to 23.7%) in the 
IXE versus ADA group. Significant differences in PASI75 and 
PASI90 response were observed as early as the first assessment 
at week 4. No significant differences were observed in NAPSI 
fingernails=0 response between treatment groups (treatment 
difference: 8.4%, 95% CI −1.8% to 18.6%). However, NAPSI 
fingernails change from baseline was significantly greater with 
IXE than ADA at week 24 (treatment difference: −3.37, 95% CI 
−5.40 to −1.33), with significant improvements as early as the 
first assessment at week 12.
DLQI (0, 1) response was significantly greater at week 24 in 
the IXE versus ADA group (treatment difference: 9.5%, 95% 
CI 1.4% to 17.7%), with significant differences as early as the 
first assessment at week 4. There were no statistically significant 
differences between groups in HAQ-DI MCID response (treat-
ment difference: 1.3%, 95% CI −6.9% to 9.6%).
safety
TEAEs were more common in the IXE versus ADA group 
(table 3); most were mild or moderate in severity. Discontinua-
tions due to AEs and serious AEs (SAEs) were numerically lower 
in the IXE versus ADA group. No deaths occurred during the 
study.
Safety data were analysed in the safety population at the 
time of database lock. Of the 566 randomised patients, n=70 
completed, n=52 discontinued and n=444 were ongoing in the 
open-label treatment period at the time of database lock.
Most infection-related TEAEs were mild or moderate in 
severity. Serious infections were more frequent in the ADA 
versus IXE group (see online supplementary table 3). Three 
patients discontinued due to infection-related AEs, including 
two in the ADA group (lymph node tuberculosis, pneumonia 
legionella) and one in the IXE group (arthritis bacterial). There 
were no confirmed cases of pulmonary tuberculosis. TEAEs of 
Candida infections were more frequent in the IXE group (n=7; 
four oral and three genital Candida infections) than the ADA 
group (n=2; one oral and one genital Candida infection). All 
Candida-related TEAEs resolved except one (IXE, oral Candida) 
that was ongoing at the week 24 database lock; none resulted in 
discontinuation.
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Table 2 Efficacy and health outcomes at week 24
IXe (n=283) AdA (n=283)
Treatment difference
IXe versus AdA (95% CI)
IXe versus AdA
P value
Primary endpoint
  ACR50+PASI100 102/283 (36.0)
30.4% to 41.6%
79/283 (27.9)
22.7% to 33.1%
8.1%
(0.5% to 15.8%)
0.036
Major secondary endpoints
  ACR50* 143/283 (50.5)
44.7% to 56.4%
132/283 (46.6)
40.8% to 52.5%
3.9%
(-4.3% to 12.1%)
0.338
  PASI100 170/283 (60.1)
54.4% to 65.8%
132/283 (46.6)
40.8% to 52.5%
13.4%
(5.3% to 21.6%)
0.001
PsA endpoints
  MDA 135/283 (47.7)
41.9% to 53.5%
100/283 (35.3)
29.8% to 40.9%
12.4%
(4.3% to 20.4%)
0.003
  VLDA† 49/283 (17.3)
12.9% to 21.7%
29/283 (10.2)
6.7% to 13.8%
7.1%
(1.4% to 12.7%)
0.015
  DAPSA remission (≤4)† 75/283 (26.5)
21.4% to 31.6%
51/283 (18.0)
13.5% to 22.5%
8.5%
(1.7% to 15.3%)
0.016
  DAPSA low disease activity or remission (≤14)† 174/283 (61.5)
55.8% to 67.2%
171/283 (60.4)
54.7% to 66.1%
1.1%
(-7.0% to 9.1%)
0.737
  DAPSA, LSM change from baseline (SE)† −31.74 (0.94) −30.10 (0.94) −1.64
(-3.94 to 0.66)
0.161
  PASDAS low disease activity (≤3.2)† 164/283 (58.0)
52.2% to 63.7%
147/283 (51.9)
46.1% to 57.8%
6.0%
(-2.2% to 14.2%)
0.153
  PASDAS near remission (≤1.9)† 82/283 (29.0)
23.7% to 34.3%
55/283 (19.4)
14.8% to 24.0%
9.5%
(2.5% to 16.6%)
0.009
  PASDAS, LSM change from baseline (SE)† −3.08 (0.10) −2.94 (0.10) −0.14
(-0.38 to 0.10)
0.260
  mCPDAI, LSM change from baseline (SE) −3.98 (0.14) −3.46 (0.13) −0.53
(-0.85 to −0.20)
0.002
  ACR20 195/283 (68.9)
63.5% to 74.3%
204/283 (72.1)
66.9% to 77.3%
−3.2%
(-10.7% to 4.3%)
0.403
  ACR70 90/283 (31.8)
26.4% to 37.2%
73/283 (25.8)
20.7% to 30.9%
6.0%
(-1.4% to 13.5%)
0.111
  SPARCC Enthesitis Index=0‡ 107/189 (56.6)
49.5% to 63.7%
77/171 (45.0)
37.6% to 52.5%
11.6%
(1.3% to 21.9%)
0.019
  LEI=0§ 95/159 (59.7)
52.1% to 67.4%
81/147 (55.1)
47.1% to 63.1%
4.6%
(-6.4% to 15.7%)
0.432
  LDI-B=0¶ 37/42 (88.1)
78.3% to 97.9%
54/58 (93.1)
86.6% to 99.6%
−5.0%
(-16.8% to 6.8%)
0.658
Skin and nail psoriasis endpoints
  PASI75 227/283 (80.2)
75.6% to 84.9%
195/283 (68.9)
63.5% to 74.3%
11.3%
(4.2% to 18.4%)
0.002
  PASI90 203/283 (71.7)
66.5% to 77.0%
158/283 (55.8)
50.0% to 61.6%
15.9%
(8.1% to 23.7%)
<0.001
  NAPSI fingernails=0** 111/191 (58.1)
51.1% to 65.1%
88/177 (49.7)
42.4% to 57.1%
8.4%
(-1.8% to 18.6%)
0.082
  NAPSI, LSM change from baseline (SE) −15.89 (0.82) −12.53 (0.82) −3.37
(-5.40 to −1.33)
0.001
Quality of life endpoints
  HAQ-DI ≥0.35†† 168/252 (66.7)
60.8% to 72.5%
166/254 (65.4)
59.5% to 71.2%
1.3%
(-6.9% to 9.6%)
0.741
  DLQI (0, 1) 174/283 (61.5)
55.8% to 67.2%
147/283 (51.9)
46.1% to 57.8%
9.5%
(1.4% to 17.7%)
0.020
Unless otherwise indicated, values are presented as n/N (%), 95% CI.
*The treatment difference of IXE minus ADA was 3.9% (95% CI −4.3% to 12.1%). The lower bound of the 95% CI (−4.3%) was greater than −12%, thus meeting noninferiority criteria.
†Post hoc analysis.
‡Assessed for patients with SPARCC Enthesitis Index score >0 at baseline.
§Assessed for patients with LEI score >0 at baseline.
¶Assessed for patients with LDI-B score >0 at baseline.
**Assessed for patients with NAPSI fingernails score >0 at baseline.
††Assessed for patients with HAQ-DI score ≥0.35 at baseline. A response of ≥0.35 change from baseline is the minimal clinically important difference in HAQ-DI.
ACR, American College of Rheumatology; ADA, adalimumab; DAPSA, Disease Activity in Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire–Disability Index; IXE, 
ixekizumab; LDI-B, Leeds Dactylitis Index–Basic; LEI, Leeds Enthesitis Index; LSM, least squares mean; mCPDAI, modified Composite Psoriatic Disease Activity Index; MDA, minimal disease activity; NAPSI, Nail Psoriasis 
Area and Severity Index; PASDAS, psoriatic arthritis disease activity score; PASI, Psoriasis Area and Severity Index; SPARCC, Spondyloarthritis Research Consortium of Canada; VLDA, very low disease activity.
Injection-site reactions were more frequent in the IXE versus 
ADA group; most were mild in severity. One severe injection-site 
reaction (injection site hypersensitivity) occurred in the ADA 
group, and one SAE (injection-site rash) occurred in the IXE 
group. Discontinuations due to injection-site reactions occurred 
in one IXE-treated and three ADA-treated patients. Most treat-
ment-emergent allergic/hypersensitivity events were mild or 
moderate in severity, all were nonanaphylactic and none were 
SAEs. One ADA-treated patient discontinued due to an allergic/
hypersensitivity event (hypersensitivity).
One serious treatment-emergent cerebrocardiovascular 
event occurred in each treatment group (IXE: atrial fibrillation; 
ADA: myocardial ischaemia). One IXE-treated patient discon-
tinued due to a treatment-emergent cerebrocardiovascular 
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Figure 2 Clinical response rates for primary and major secondary 
outcomes through week 24 (non-responder imputation). (A) Percentage 
of patients simultaneously achieving ACR50 and PASI100 (primary 
endpoint). (B) Percentage of patients achieving ACR50 (major secondary 
endpoint). The treatment difference of IXE minus ADA was 3.9% (95% 
CI −4.3% to 12.1%). The lower bound of the 95% CI (−4.3%) was 
greater than −12%, thus meeting noninferiority criteria. (C) Percentage 
of patients achieving PASI100. IXE versus ADA: *P<0.05, †p<0.01, 
‡p<0.001. ACR, American College of Rheumatology; ADA, adalimumab; 
IXE, ixekizumab; PASI, Psoriasis Area Severity Index.
Figure 3 Clinical response rates for treat-to-target outcomes 
through week 24. (A) Percentage of patients achieving minimal 
disease activity. (B) Percentage of patients achieving very low disease 
activity. (C) Percentage of patients achieving a DAPSA score of ≤14 
(LDA or remission). (D) Percentage of patients achieving a DAPSA 
score ≤4 (remission). IXE versus ADA: *P<0.05, †p<0.01, ‡p<0.001. 
ADA, adalimumab; DAPSA, Disease Activity in Psoriatic Arthritis; IXE, 
ixekizumab; LDA, low disease activity.
event of bradycardia. One major adverse cerebrocardiovas-
cular event of moderate haemorrhagic stroke occurred in 
the ADA group; this event was an SAEand did not result in 
discontinuation.
No treatment-emergent malignancies occurred in the IXE 
group, and three occurred in the ADA group, two of which 
were considered by the investigator as SAEs (basal cell carci-
noma and rectal neoplasm). No patients discontinued due to 
malignancy. No TEAEs of cytopaenia were SAEs, and none 
resulted in discontinuation. No patients had a worsening to 
grade 3 or 4 neutropenia. There were no suicide or self-in-
jury-related TEAEs in either group. There were no depres-
sion-related SAEs, and no patients discontinued due to 
depression-related TEAEs.
Suspected IBD-related events were adjudicated by an expert 
panel as defined by the EPIdemiologique des Maladies de l’Appareil 
Digestif (EPIMAD) criteria for adjudication of suspected IBD, 
where ‘probable’ and ‘definite’ classifications are considered as 
confirmed cases.14 Three TEAEs were identified in two IXE-treated 
patients as suspected IBD. One IXE-treated patient had an event 
reported as ‘colitis’ that was sent for adjudication, but there was 
insufficient information to make a definitive classification. The 
same patient also had an event of ‘colitis ulcerative’, adjudicated as 
possible ulcerative colitis, which resulted in study discontinuation. 
Another IXE-treated patient with no prior medical history of IBD 
had an event reported as ‘colitis’ that was adjudicated as probable 
Crohn’s disease and was the only case that met EPIMAD criteria 
for confirmed IBD. No SAEs of IBD occurred, and no TEAEs of 
potential IBD were reported in the ADA group.
dIsCussIOn
Treatment choices for PsA in clinical practice are made 
between medications that have shown efficacy and sufficient 
safety in clinical trials. Because comparative clinical trials 
are rare in PsA, indirect comparisons are often made using 
meta-analyses. However, head-to-head trials where active 
agents are compared, rather than an active agent and placebo, 
offer the highest level of evidence.15–18 The SPIRIT-P1 and 
OPAL trials (which compared IXE or tofacitinib, respectively, 
with placebo) included an ADA active reference arm but were 
not powered for head-to-head comparisons with ADA.11 19 A 
study (EXCEED 1) comparing replacement of csDMARDs 
with secukinumab or adalimumab monotherapy is ongoing 
(NCT02745080). Although both SPIRIT-H2H and EXCEED 
1 included bDMARD-naïve patients with inadequate response 
to csDMARDs, key differences between the studies include 
blinding (double-blind in EXCEED 1 vs open-label in SPIR-
IT-H2H) and concomitant csDMARD use (not allowed in 
EXCEED 1). SPIRIT-H2H is the first completed head-to-head 
trial comparing two bDMARDs in patients with active PsA and 
inadequate response to csDMARDs.
Although skin involvement is usually mild in patients with PsA, 
clinicians and patients judge the impact of a PsA treatment by 
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Table 3 Safety outcomes
IXe (n=283) AdA (n=283)
Extent of exposure, mean days (total patient-
years)
236.8 (183.5) 228.9 (117.3)
Treatment-emergent adverse events 197 (69.6) 173 (61.1)
  Mild 97 (34.3) 87 (30.7)
  Moderate 91 (32.2) 71 (25.1)
  Severe 9 (3.2) 15 (5.3)
Serious adverse events 10 (3.5) 24 (8.5)
Deaths 0 0
Discontinuations due to adverse events 7 (2.5) 13 (4.6)
Adverse events of special interest
  Infections 102 (36.0) 87 (30.7)
  Serious infections 4 (1.4) 8 (2.8)
  Candida infections 7 (2.5) 2 (0.7)
Injection-site reactions 27 (9.5) 9 (3.2)
Allergic/hypersensitivity reactions 7 (2.5) 11 (3.9)
  Potential anaphylaxis 0 0
Cytopaenias 5 (1.8) 11 (3.9)
Cerebrocardiovascular events* 3 (1.1) 5 (1.8)
Malignancies 0 3 (1.1)
Depression 3 (1.1) 7 (2.5)
Inflammatory bowel disease 2 (0.7)† 0
  Ulcerative colitis 1 (0.4)‡, 0
  Crohn’s disease 1 (0.4)§ 0
Safety data were analysed in the safety population at the time of database lock. 
Of the 566 randomized patients, n=70 completed, n=52 discontinued, and n=444 
were ongoing in the open label treatment period at the time of database lock.
*Of eight treatment-emergent cerebrocardiovascular events reported, four (IXE: 
n=2 (0.7%); ADA: n=2 (0.7%)) were adjudicated.
†EPIdemiologique des Maladies de l’Appareil Digestif (EPIMAD) criteria for 
adjudication of suspected inflammatory bowel disease define ‘probable’ and 
‘definite’ classifications as confirmed cases. Only one case met the EPIMAD criteria 
of confirmed inflammatory bowel disease.
‡Event was reported as colitis ulcerative and was adjudicated as possible ulcerative 
colitis.
§Event was reported as colitis and was adjudicated as probable Crohn’s disease.
ADA, adalimumab; IXE, ixekizumab.
effects on all domains affected by the disease, in particular joints 
and skin.20–22 Furthermore, achievement of optimal health-related 
quality of life, the ultimate treatment goal in PsA, requires improve-
ments in both joint and skin manifestations of the disease.1 There-
fore, a combination of two validated and well-established outcome 
measures, a relatively stringent endpoint for articular disease 
(ACR50) and a very stringent endpoint for skin disease (PASI100) 
was employed as the primary endpoint. The 24-week efficacy data 
from the present study demonstrate that IXE was superior to ADA 
in simultaneously leading to an ACR50 and PASI100 response, was 
non-inferior to ADA for achieving ACR50 and was superior to ADA 
for achieving PASI100. Furthermore, significantly more patients 
achieved DAPSA remission (which does not include a measure of 
skin response) with IXE than ADA, suggesting that skin changes were 
not the only domain contributing to differences between biologics. 
IXE further demonstrated significantly higher clinical response 
rates than ADA at week 24 for SPARCC Enthesitis Index, psoriasis 
(PASI75/90), fingernail psoriasis (NAPSI fingernails change from 
baseline), mCPDAI and treat-to-target endpoints of MDA, VLDA 
and DAPSA remission.23 Rapid and significantly greater improve-
ments in skin-related quality of life were also observed (DLQI (0 
or 1)). No significant differences were observed between treatment 
groups for ACR20/50/70, suggesting IXE had similar speed and 
level of response compared to ADA for joint improvement.
SAEs, especially those related to infections, were numeri-
cally higher in the ADA group. Infections were more frequent 
in the IXE group than the ADA group. Injection site reactions 
(including injection site pain) were numerically higher in the IXE 
arm, although most were mild in both groups. Overall, the safety 
profiles of both bDMARDs were consistent with those described 
in the prescriber information.
A key strength of the SPIRIT-H2H study is its relevance to 
real-world clinical settings. The open-label study design and 
absence of a placebo arm was modelled after real-world clinical 
settings where patients receive active treatments and are aware 
of which treatment they receive. Patients were treated with the 
approved dosing regimens of both IXE and ADA (according to 
presence/absence of moderate-to-severe psoriasis), as mono-
therapy or in combination with csDMARDs. Approximately 
82% of patients did not meet criteria for moderate-to-severe 
psoriasis, consistent with the patient population typically seen 
by rheumatologists.20–22
Although comparisons between clinical studies are limited by 
differences in design and study population, joint and skin responses 
for both IXE and ADA were higher in SPIRIT-H2H than in histor-
ical studies.10 11 24 The use of two efficacious treatments, open-label 
study design and lack of a placebo arm may have contributed to 
increased responses in SPIRIT-H2H, since all patients knew they 
would receive active therapy. To minimise bias, key outcomes 
were measured by blinded assessors. However, an expectation of 
different rates of improvement (especially in skin outcomes) with 
IXE versus ADA could potentially influence blinded assessors. 
However, this limitation also exists for double-blind, placebo-con-
trolled studies, where greater response is expected with an active 
treatment versus a placebo comparator. SPIRIT-H2H is ongoing 
through 52 weeks of treatment, and the current report is limited 
to 24 weeks. Thus, it is currently unknown how clinical responses 
will compare over longer treatment periods. An additional study 
limitation was the absence of imaging or structural joint damage 
assessments. Though the patient population in this study is similar 
to other clinical trials in PsA, it may not represent all patients with 
PsA in daily clinical practice (eg, patients in this study predomi-
nantly had polyarthritis).
In conclusion, IXE was associated with greater improvement 
of a combined articular and cutaneous endpoint in PsA compared 
with ADA over a 24-week period and had numerically lower inci-
dence of SAEs compared to ADA.
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